US-20260128144-A1 - Systems and Methods for Pharmacotherapeutic Intervention in Obesity Treatment Targeting Multiple Neurophysiological Mechanisms Using Patient Phenotyping Modeling

US20260128144A1US 20260128144 A1US20260128144 A1US 20260128144A1US-20260128144-A1

Abstract

Systems and methods for pharmacotherapeutic intervention in obesity treatment are disclosed, targeting multiple neurophysiological mechanisms of appetite and weight regulation. The described technology utilizes patient phenotyping, including body mass index (BMI), medical history, and laboratory data, to classify patients and select individualized therapies. Solutions include administering non-GLP-1 agonist anti-obesity medications, dual therapies, or agents targeting GLP-1 and GIP receptors, combined with lifestyle modifications (diet, physical activity). The approach aims to achieve significant and durable weight loss while minimizing compensatory physiological responses, with periodic re-evaluation and treatment updates. An AI-driven decision support tool may be used for personalized recommendations. Principal uses include treating patients with varying BMI ranges and comorbidities, including type 2 diabetes mellitus, to improve metabolic health and quality of life. The described method is characterized by selecting and administering pharmacotherapy based on patient classification and ongoing assessment.

Inventors

David H. Bass
Leon Igel
Christina Lorenzo
Cheryl Pegus
Nathan Lesch
Guadalupe Minero
Venkateswaran Suriyanarayanan

Assignees

Intellihealth, Inc.

Dates

Publication Date: 20260507
Application Date: 20251030

Claims (19)

1 . A method of selecting a pharmacotherapeutic intervention for treatment of obesity targeting multiple dedicated neurophysiological mechanisms of appetite and weight regulation to achieve significant and durable weight loss for a classified patient with a Body Mass Index (BMI) of 27 to 29.9, the method comprising: receiving patient data comprising at least body-mass-index (BMI), medical history, laboratory data, and prior medication response; classifying a patient into a predefined BMI range using the patient data, the predefined BMI range being a Body Mass Index (BMI) of 27 to 29.9 thereby the classified patient being classified as overweight; determining, for the classified patient, an absence of type-2 diabetes mellitus using the patient data; receiving a lifestyle modification confirmation for the classified patient, the lifestyle modification confirmation for the classified patient being that the classified patient makes a lifestyle modification; administering a therapeutically effective amount of a non-glucagon-like peptide-1 (non-GLP-1) agonist anti-obesity medication to the classified patient, the administering the therapeutically effective amount of the non-GLP-1 agonist anti-obesity medication to the classified patient being a particular prophylaxis targeting multiple dedicated neurophysiological mechanisms that is an obesity treatment for patients having a Body Mass Index (BMI) of approximately 27 to 29.9 in combination with the lifestyle modification confirmation; and re-evaluating the classified patient and updating a medical treatment plan of the classified patient based on the re-evaluating.
2 . The method of claim 1 , wherein the non-glucagon-like peptide-1 (non-GLP-1) agonist anti-obesity medication is at least one of: metformin, topiramate, zonisamide, bupropion, naltrexone, phentermine, and orlistat.
3 . The method of claim 1 , wherein the lifestyle modification confirmation comprises confirmation that the classified patient adopts a hypocaloric diet or increases physical activity to a target of at least 150 minutes per week.
4 . The method of claim 1 , wherein re-evaluating the classified patient comprises measuring a body weight of the classified patient and reassessing body-mass-index (BMI) after a three-month interval.
5 . The method of claim 1 , wherein determining the absence of type-2 diabetes mellitus comprises analyzing a glycated hemoglobin (HbA1c) level of the classified patient to confirm that the glycated hemoglobin (HbA1c) level is below 6.5%.
6 . The method of claim 1 , further comprising generating a clinician-facing report that lists a selected pharmacotherapeutic regimen, recommended dosing schedule, and a scheduled re-evaluation date.
7 . A method of selecting a pharmacotherapeutic intervention for treatment of obesity targeting multiple dedicated neurophysiological mechanisms of appetite and weight regulation to achieve significant and durable weight loss for a classified patient with a Body Mass Index (BMI) of 30 to 34.9, the method comprising: receiving patient data comprising at least body-mass-index (BMI), medical history, laboratory data, and prior medication response; classifying a patient into a predefined BMI range using the patient data, the predefined BMI range being a Body Mass Index (BMI) of 30 to 34.9 thereby the classified patient being classified in class 1 of obesity; determining, for the classified patient, an absence of type-2 diabetes mellitus using the patient data; determining, for the classified patient, an absence of history or current diagnosis of myocardial infarction, stroke, chronic heart failure, hypertension, obstructive sleep apnea, or non-alcoholic fatty liver disease; receiving a lifestyle modification confirmation for the classified patient, the lifestyle modification confirmation for the classified patient being that the classified patient makes a lifestyle modification; administering a therapeutically effective amount of dual therapy non-glucagon-like peptide-1 (non-GLP-1) agonist anti-obesity medications to the classified patient, the administering the therapeutically effective amount of the dual therapy non-GLP-1 agonist anti-obesity medications to the classified patient being a particular prophylaxis targeting multiple dedicated neurophysiological mechanisms that is an obesity treatment for patients having a Body Mass Index (BMI) of approximately 30 to 34.9 in combination with the lifestyle modification confirmation; and re-evaluating the patient and updating a medical treatment of the patient based on the re-evaluating.
8 . The method of claim 7 , wherein the dual therapy non-glucagon-like peptide-1 (non-GLP-1) agonist anti-obesity medications comprise a combination selected from the group consisting of metformin and bupropion, metformin and topiramate, bupropion and topiramate, bupropion and naltrexone, phentermine and topiramate, and phentermine and metformin.
9 . The method of claim 7 , wherein the lifestyle modification comprises adoption of an increase in physical activity for the classified patient to a target of at least 150 minutes per week.
10 . The method of claim 7 , wherein re-evaluating the classified patient comprises measuring a body weight of the classified patient and reassessing body-mass-index (BMI) after a three-month interval.
11 . A method of selecting a pharmacotherapeutic intervention for treatment of obesity targeting multiple dedicated neurophysiological mechanisms of appetite and weight regulation to achieve significant and durable weight loss for a classified patient with a Body Mass Index (BMI) of 35 to 39.9, the method comprising: receiving patient data comprising at least body-mass-index (BMI), medical history, laboratory data, and prior medication response; classifying a patient into a predefined BMI range using the patient data, the predefined BMI range being a Body Mass Index (BMI) of 35 to 39.9 thereby the classified patient being classified in class 2 of obesity; determining, for the classified patient, an absence of type-2 diabetes mellitus using the patient data; determining, for the classified patient, an absence of history or current diagnosis of myocardial infarction, stroke, chronic heart failure, hypertension, obstructive sleep apnea, or non-alcoholic fatty liver disease; receiving a lifestyle modification confirmation for the classified patient, the lifestyle modification confirmation for the classified patient being that the classified patient makes a lifestyle modification; administering a therapeutically effective amount of dual therapy non-glucagon-like peptide-1 (non-GLP-1) agonist anti-obesity medications to the classified patient, the administering the therapeutically effective amount of the dual therapy non-GLP-1 agonist anti-obesity medications to the classified patient being a particular prophylaxis targeting multiple dedicated neurophysiological mechanisms that is an obesity treatment for patients having a Body Mass Index (BMI) of approximately 30 to 34.9 in combination with the lifestyle modification confirmation; and re-evaluating the patient and updating a medical treatment of the patient based on the re-evaluating.
12 . The method of claim 11 , wherein the dual therapy non-glucagon-like peptide-1 (non-GLP-1) agonist anti-obesity medications comprise a combination selected from the group consisting of metformin and bupropion, metformin and topiramate, bupropion and topiramate, bupropion and naltrexone, phentermine and topiramate, and phentermine and metformin.
13 . The method of claim 11 , wherein the lifestyle modification comprises adoption of an increase in physical activity for the classified patient to a target of at least 150 minutes per week.
14 . The method of claim 11 , wherein re-evaluating the classified patient comprises measuring a body weight of the classified patient and reassessing body-mass-index (BMI) after a three-month interval.
15 . A method of selecting a pharmacotherapeutic intervention for treatment of obesity targeting multiple dedicated neurophysiological mechanisms of appetite and weight regulation to achieve significant and durable weight loss for a classified patient with a Body Mass Index (BMI) of 40 or higher, the method comprising: receiving patient data comprising at least body-mass-index (BMI), medical history, laboratory data, and prior medication response; classifying a patient into a predefined BMI range using the patient data, the predefined BMI range being a Body Mass Index (BMI) of 40 or higher thereby the classified patient being classified in class 3 of obesity; determining, for the classified patient, an absence of type-2 diabetes mellitus using the patient data; receiving a lifestyle modification confirmation for the classified patient, the lifestyle modification confirmation for the classified patient being that the classified patient makes a lifestyle modification; determining, for the classified patient, a history or current diagnosis of myocardial infarction, stroke, chronic heart failure, hypertension, obstructive sleep apnea, or non-alcoholic fatty liver disease; administering a therapeutically effective amount of dual therapy non-glucagon-like peptide-1 (non-GLP-1) agonist anti-obesity medications or Gastric Inhibitory Polypeptide (GIP) agonist to the classified patient, the administering the therapeutically effective amount of the dual therapy non-GLP-1 agonist anti-obesity medications or Gastric Inhibitory Polypeptide (GIP) agonist being a particular prophylaxis targeting multiple dedicated neurophysiological mechanisms that is an obesity treatment for patients having a Body Mass Index (BMI) of 40 or higher in combination with the lifestyle modification confirmation; and re-evaluating the patient and updating a medical treatment of the patient based on the re-evaluating.
16 . The method of claim 15 , wherein the dual therapy non-glucagon-like peptide-1 (non-GLP-1) agonist anti-obesity medications comprise a combination selected from the group consisting of metformin and bupropion, metformin and topiramate, bupropion and topiramate, bupropion and naltrexone, phentermine and topiramate, and phentermine and metformin.
17 . The method of claim 15 , wherein the lifestyle modification comprises adoption of an increase in physical activity for the classified patient to a target of at least 150 minutes per week.
18 . The method of claim 15 , wherein re-evaluating the classified patient comprises measuring a body weight of the classified patient and reassessing body-mass-index (BMI) after a three-month interval.
19 . A method of pharmacotherapeutic intervention for treatment of obesity targeting multiple dedicated neurophysiological mechanisms of appetite and weight regulation to achieve significant and durable weight loss for a patient that has a diagnosis of type 2 diabetes mellitus, the method comprising: ascertaining a patient has a diagnosis of type 2 diabetes mellitus; determining a recent hemoglobin A1c level to be either below 9% or greater than 9% for the patient; determining a recent hemoglobin A1c level is greater than 9%; determining if a most recent c-peptide level is either low or normal/high; determining the most recent c-peptide level is normal/high; determining if the patient is on metformin or contraindicated for metformin; determining the recent hemoglobin A1c level is between 9% to 10%; and administering a therapeutically effective amount of medications to the patient targeting either Glucagon-Like Peptide-1 (GLP-1) receptors or both Glucagon-Like Peptide-1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) receptors, the administering being a particular prophylaxis targeting multiple dedicated neurophysiological mechanisms that is a specific obesity treatment for patients having a diagnosis of type 2 diabetes mellitus and a recent hemoglobin A1c level between 9% to 10%.

Description

CROSS REFERENCE TO RELATED APPLICATIONS This application claims the priority benefit of U.S. Provisional Patent Application Ser. No. 63/716,064, filed on Nov. 4, 2024, and titled “Systems and Methods for Pharmacotherapeutic Intervention in Obesity Treatment Targeting Multiple Neurophysiological Mechanisms Using Patient Phenotyping Modeling.” The aforementioned disclosure is hereby incorporated by reference in its entirety for all purposes. FIELD OF THE TECHNOLOGY This disclosure relates generally to medical technologies, specifically pharmacotherapeutic interventions for obesity treatment and obesity-related comorbidities using patient phenotyping modeling BACKGROUND In recent years, obesity and related metabolic disorders have become a significant concern globally. Medical technologies aimed at body-weight regulation span a wide range of interventions, including dietary, behavioral, surgical, and pharmacological strategies. Among these, pharmacotherapeutic approaches seek to modulate neurophysiological systems that govern appetite, satiety, energy expenditure, and nutrient absorption. Advances in diagnostic methods and patient-phenotyping tools have raised the possibility of tailoring treatments to individual physiological and genetic profiles. Nonetheless, the intricate and dynamic nature of weight-regulation mechanisms poses ongoing challenges for clinicians and researchers striving to translate scientific insights into safe and effective therapies. Efforts to treat obesity focus not only on achieving initial weight reduction but also on sustaining long-term improvements in metabolic health and quality of life. Desired outcomes include lowering cardiovascular risk factors, reducing incidence of type 2 diabetes and fatty liver disease, and alleviating obesity-associated respiratory and musculoskeletal complications. In clinical practice, interventions are expected to harmonize pharmacological regimens with lifestyle modifications, such as tailored dietary plans, structured physical activity, and behavior support, to optimize adherence and minimize adverse effects. Health care providers aim to deliver individualized guidance based on patient history, comorbidities, and treatment responsiveness, with the primary objective of improving overall health metrics while maintaining patient safety and tolerance. Traditional approaches for weight management, including caloric restriction and exercise, frequently fail to yield sustained results. Physiological safeguards designed to preserve energy stores activate in response to reduced intake and increased activity, slowing basal metabolic rate and heightening appetite signals. These compensatory adaptations often manifest as increased hunger, reduced satiety, and metabolic adaptation that blunts energy expenditure. As a result, patients commonly experience plateaus or regain lost weight, which can undermine motivation and long-term success. Moreover, variability in individual responses to behavioral interventions further complicates treatment planning, highlighting limitations in the capacity of conventional regimens to produce durable weight loss across diverse patient populations. Pharmacological solutions that target a single neurophysiological pathway have demonstrated modest efficacy, yet their benefits frequently diminish over time. When one regulatory mechanism is suppressed or enhanced, alternative circuits may be recruited to re-establish homeostasis, thereby attenuating initial weight reductions. This counter-regulatory phenomenon underscores the complexity of appetite and energy-balance systems, which involve overlapping networks of hormones, neurotransmitters, and signaling cascades. Additionally, individual variations in receptor profiles, hormonal set points, and metabolic rate contribute to inconsistent clinical outcomes. As a result, there remains a pressing need for therapeutic strategies capable of simultaneously addressing multiple weight-regulating pathways, thereby minimizing compensatory responses, and improving the durability of treatment effects. SUMMARY Some embodiments relate to a method of selecting a pharmacotherapeutic intervention for treatment of obesity targeting multiple dedicated neurophysiological mechanisms of appetite and weight regulation to achieve significant and durable weight loss for a classified patient with a Body Mass Index (BMI) of 27 to 29.9, the method including: receiving patient data including at least body-mass-index (BMI), medical history, laboratory data, and prior medication response; classifying a patient into a predefined BMI range using the patient data, the predefined BMI range being a Body Mass Index (BMI) of 27 to 29.9 thereby the classified patient being classified as overweight; determining, for the classified patient, an absence of type-2 diabetes mellitus using the patient data; receiving a lifestyle modification confirmation for the classified patient, the lifestyle modification confirmation for the c